TCR2 Therapeutics (NASDAQ:TCRR – Get Rating) was downgraded by analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday, The Fly reports. They presently have a $3.00 price target on the stock, down from their previous price target of $18.00. Jefferies Financial Group’s target price would suggest a potential upside of 109.79% from the company’s previous close.
Other equities research analysts also recently issued reports about the stock. HC Wainwright downgraded shares of TCR2 Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday. Piper Sandler boosted their price target on shares of TCR2 Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Thursday, January 5th. EF Hutton Acquisition Co. I assumed coverage on shares of TCR2 Therapeutics in a report on Thursday, January 5th. They set a “hold” rating and a $2.00 price target on the stock. Finally, Truist Financial cut shares of TCR2 Therapeutics from a “buy” rating to a “hold” rating and cut their price target for the stock from $8.00 to $3.00 in a report on Tuesday. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $6.20.
TCR2 Therapeutics Price Performance
NASDAQ:TCRR opened at $1.43 on Thursday. The firm has a 50-day moving average of $1.30 and a 200-day moving average of $1.54. The company has a market cap of $55.28 million, a PE ratio of -0.46 and a beta of 1.90. TCR2 Therapeutics has a one year low of $0.82 and a one year high of $3.88.
Institutional Trading of TCR2 Therapeutics
About TCR2 Therapeutics
TCR2 Therapeutics, Inc is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development.
- Get a free copy of the StockNews.com research report on TCR2 Therapeutics (TCRR)
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- How to Buy High Yielding Dividend Stocks
- Oracle Has Spoken: Shares Fall 5%
Receive News & Ratings for TCR2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TCR2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.